DNA copy number aberrations (CNA) were frequently observed in colorectal cancers (CRC).
INTRODUCTION
Extensive copy number aberrations (CNA) are a hallmark of cancers with genome instability and are observed among a wide variety of epithelial malignancies originating from the colon, breast, cervix, prostate, bladder and stomach 1 . High levels of CNAs are associated with cancer progression and poor prognosis. Thus, there is general interest in profiling CNAs as potential biomarkers associated with specific clinical outcome.
The focus of our study was colorectal cancer (CRC), the third most common cancer worldwide, with ~1. 8 Citing some examples, with karyotyping, Bardi et al. found that loss of chromosome 18 was correlated with shorter overall survival in early-stage patients (N=150) 2 . Personeni et al. 3 using FISH identified that changes in EGFR copy number predicted overall survival for EGFR-targeted therapy in a metastatic CRC cohort (N=87). Using SNP-arrays, Sheffer et al. identified deletions of 8p, 4p, and 15q were associated with poor survival in a mixedstage cohort (N=130) 4 . Other microarray-based studies [5] [6] [7] using smaller numbers of patients (N<100) identified various CNAs associated with poor survival that included sub-arm losses of 1p, 4p, 5, 6, 8p, 10, 14q, and 18. In contrast, based on CGH-array analysis, Rooney et al. 8 reported that no specific CNA was significantly associated with survival in Duke's C-stage CRCs (N=29). The lack of concordance among these studies reflects the clinical stage variation among the study cohorts and the inherent limits of the molecular methods used for detecting CNAs and suggests clinical stage-specific variation among the study cohorts.
More recently, researchers have employed whole genome (WGS), whole exome (WES), and targeted sequencing for high-resolution analysis to profile CNAs. WGS has significant advantages over the other approaches because it provides whole-genome coverage without targeting and capturing as compared to other methods including microarrays and exomes.
Exome and targeted sequencing have technical biases due to the extra DNA amplification and hybridization steps. Furthermore, these methods with their emphasis on gene targets cover only a small proportion (<3%) of the genome and thus miss significant portions of the noncoding genome which are noncoding. However, conducting high-coverage WGS is costly even when considering recent cost reductions in sequencing. It also generates large data sets that incur significant informatics cost.
To overcome some of the challenges of conducting cancer WGS studies on populations, we developed a low-coverage whole genome approach that provided highly accurate genomewide copy number results. As a result, this leads to a significantly lower per sample cost than conventional WGS. For this study, we used an average sequencing coverage of less than 5X. Moreover, this WGS approach was optimized for sequencing formal fixed paraffin embedded (FFPE) samples, thus enabling our approach to be widely used for archival pathology biopsies. We verified the accuracy of CNA segments generated with this approach using a systematic benchmark with microarray, WES and high-coverage WGS. Overall, development of this low-coverage WGS enabled us to analyze the entire genome for CNAs while reducing the sequencing cost and bioinformatic workload.
We applied this WGS approach to a Stage III CRC cohort. Among the different clinical stages of CRC, there is a particular interest in identifying CNAs that indicate poor prognosis for individuals with Stage III disease, where local lymph node involvement is present without imaging or pathologic evidence of distal metastasis. These patients routinely receive adjuvant chemotherapy and yet, there is a significant fraction that show recurrence despite receiving adjuvant treatment after complete resection of their cancers. Identifying Stage III patients at high risk for recurrence may prove useful in targeting these individuals for more effective adjuvant regimens and developing more sensitive screening protocols for detecting early metastasis.
We conducted a WGS analysis on a discovery cohort of Stage III CRCs (N=134). We determined whether any specific CNAs were associated with a poor survival within the cohort.
We validated our results with an independent cohort of Stage III CRCs from the Cancer Genome Atlas (TCGA) project (N=187). Our findings provided additional evidence to support that specific CNAs are predictive for CRC progression, having identified a specific genomic deletion that is predictive for lower overall survival.
RESULTS

Copy number calling
We benchmarked genome segmentation by bioinformatics tools such as CNVkit and Bic-seq on low-coverage WGS data with a randomly selected set of 10 tumor-normal matched CRCs from TCGA (Fig. 1) . Their copy number analysis data were also publicly available from SNP microarrays. Using either caller, we observed that the WGS-derived genome segments were highly correlated with the microarray segments, which were considered as ground-truth (Fig. 2) . The genome-wide tile-based average PCC were, 0.966 and 0.963 for CNVkit and Bic-Seq, respectively, and the gene-based ones were 0.943 and 0.938. We observed no statistically significant difference between PCC metrics of CNVkit and Bic-seq (Wilcoxon's P=0.68). We selected CNVkit because of its consistent performance with a relatively smaller median absolute deviation (i.e. intra-tile deviation metrics): 0.0088 vs 0.0113.
We examined the potential variability and bias as related to low average coverage. For this evaluation, we sequenced eight pilot tumor-normal pairs at a higher coverage at ~30x and these high-coverage WGS data were down-sampled to ~3x. We found high correlations between low-and high-coverage WGS segments with an average PCC at 0.93 (Fig. 2) . We identified the only three samples that had PCC<0.9 all had tumor purity <40% (Wilcoxon's P=0.036), suggesting that the sensitivity of detection could be limited by the poor sample quality given an adequate coverage (>2x).
We compared genome segmentation results between low-coverage WGS and WES platforms. We found a general agreement between methods although the WES CNV estimates had a higher level of noise. Within a genome tile size of 100kb, we did not generally expect abrupt copy number changes within a tile, therefore the intra-tile CNR deviation are mostly because of experimental variability as related to the sequencing preparation. We found that the mean intra-tile copy number ratio deviation (as measured by median absolute deviation) was much higher in WES derived segmentations as compared to low-coverage WGS (Wilcoxon's P=0.00018). Specifically, the intra-tile deviation metric was as small as <0.1 for WGS while it was 1.09 for WES. Our results point to WES-derived segments being highly variable, which is apparent from visual inspection of the segmentation tracks compared to WGS from the same sample (see an example in Supplementary Fig. 1 ).
Copy number features associated with clinical parameters
Using a discovery cohort of 134 tumor-normal pairs, we conducted WGS analysis and identified CNAs. The cohort consisted of Stage III CRCs originating from patients that were diagnosed between 2001 and 2015 ( Table 1) . We examined demographic (gender, ethnicity, age) and relevant clinical variables (treatment, sideOfColon, cancerGrade, recurrence, BMI, smokingStatus) associated with overall survival. The right side of colon was defined as any of "ascending colon", "appendix", "cecum", "hepatic flexure", "transverse" and the left side of colon was defined as any of "descending colon", "rectosigmoid junction", "sigmoid colon", "splenic flexure".
Among these Stage III CRC patients, 74 (55%) received adjuvant chemotherapy -treatment occurred with either 5-fluoruracil-based (5-FU) or capecitabine regimen. Patients undergoing adjuvant chemotherapy had a statistically significant improved survival as expected 9, 10 , with a relative reduction of death risk >58% (HR= 0.416, 95% CI=[0.239, 0.724], P= 0.00195). These patients had a median overall survival of more than a year longer than that of patients who did not receive any therapy.
Stage III CRC patients with a primary tumor located in the left colon had a statistically significant improved survival with a relative reduction of death risk >42% (HR= 0.576, 95% CI= [0.342, 0.971], P= 0.0382). These patients had a median overall survival that was approximately one-half year (181 days) longer than that of patients had tumor occurred to the right of the colon.
Analysis of recurrent arm-level CNAs
We observed extensive focal-and arm-level CNAs among the Stage III CRC discovery cohort ( Fig. 3 ). As has been widely reported and is seen with samples exhibiting CNAs, >85% of CRC are CIN phenotype and this percentage is even higher for advanced CRCs for CIN's known to be associated with poor prognosis. The Gistic2 analysis revealed that more than half of the samples showed CNA gains of chr7, chr8q, chr13q and chr20q. And almost a half of the samples had CNA loss in chr17p and chr18.
The frequency of recurrent CNA gains or losses identified in the discovery cohort were concordant with the frequency observed in the TCGA stage III validation cohort. With a q-value of <0.25 and a 99% confidence as our statistical thresholds (Gistic2), we identified 21 armlevel CNAs that were statistically significant ( Fig. 4) . Seventeen CNAs were also significantly recurrent in the Stage III TCGA cohort. These included amplifications of chr1q, chr7, chr8q, chr13q and chr20, and deletions of chr1p, chr4, chr5q, chr15q, chr17p, chr18, chr21q and chr22q. Overall, the concordance of statistically significant recurrent arm-level CNAs between the two cohorts was >81%.
Chromosome arm 17p loss is associated with poor overall survival
We applied lasso-regularized multivariate cox regression to select for significant arm-level events predictive of patients' overall survival (Methods). We identified the loss of chr17p as the single and most significant arm-level event associated with overall survival. This significance was apparent using a non-zero regression coefficient. By our final multivariate model (Eq. 2), the loss of chr17p was a significant predictor of lower overall survival (P=0.0160, HR=1.706, 95% CI=[1.104-2.635]). Any patient carrying 17p deletion was associated with a 68.8% increased risk of death. An increased risk was also clear by examining the resulting Kaplan-Meijer curves when patients were stratified by their 17p loss status (Fig. 3) . Other factors including gender, ethnicity and age at diagnosis were not associated with overall survival. After adjusting for 17p-loss, the patients having CRC occurred to the left side of colon still had a relative reduction of death risk >33%, however, the effect ceased to be statistically significant with a marginal P=0.0727, likely a sensitivity limit imposed by the sample size. Nonetheless, patients receiving adjuvant therapy, i.e. treatment, (P=0.002, HR=0.478, 95% CI= [0.299-0.765]) were benefitting from a significant reduction of risk of death (52.2%) after adjusting for 17p-loss. This statistically significant difference in survival is also visible as an enrichment of shorter survival patients within the strata of carrying 17p-loss ( Fig. 3) .
For our validation analysis, we employed the same multivariate cox model to the TCGA cohort data. Using this completely independent data set, we again confirmed that the loss of Using our discovery cohort, we examined whether patients treated with adjuvant CRC patients (N = 69) had a lower overall survival based on 17p copy number. A 17p-loss was associated with an increased death risk at HR=1.457, CI=[0.855,2.482], P=0.166. Thus, a trend towards lower survival in the setting of adjuvant therapy was noted but the sample size was too small to reach statistical significance.
Chromosome arm 17p loss is associated with increased chromosomal instability.
TP53, a critical tumor suppressor involved in genome stability, is located on the 17p arm.
Point mutations involving TP53 were associated with poor survival in colorectal cancers 11 , as indicator of TP53 loss-of-function 12 . We compared both the focal-and arm-level CIN, as represented by the total counts of CNAs, between patients carrying or not carrying the 17p loss ( Fig. 4) . We confound consistently higher CIN scores in patients carrying the 17p loss (one sided T-test, P=2.6e-9 for focal and P=2e-10 for arm-level CIN, respectively). This increase is notable in Fig. 3 , where almost all patients had chr17p loss had significant copy number changes globally, indicative of a CIN subtype.
The loss of 17p thus could be an indicator for the loss of TP53 function which is known to contribute to CIN in CRC. Vogelstein et al. theorized that the TP53 alteration occurs at relatively later stage of colon cancer and is responsible for promoting tumor invasion to surrounding normal tissue 13 . Our observation of extensive presence of 17p loss in Stage III CRCs provides additional supporting evidence to this conclusion.
DISCUSSION
This study represents one of the most comprehensive copy number analysis of Stage III CRC with the benefit of using WGS and its associated complete genome coverage and higher resolution. With these WGS results, we identified stage-specific CNA prognostic markers for Stage III CRC. Our analysis identified the loss of chromosome 17p arm, spanning TP53, as a potential biomarker for poor survival in Stage III CRC. Our results were independently validated by the TCGA cohort. Patients with 17p/TP53 deletion in their CRC tumors have 1.6 times relative death risk in general, as compared to those tumors which do not. Previous studies of CRC have used cohorts with mixed clinical stages. For example, nearly all of the studies included a higher number of CRCs from Stage I and II patients compared to Stage III and IV patients. Furthermore, nearly all the previous studies did not conduct an independent validation using a separate population of CRC patients with an independent validation study. The majority of these studies used low resolution molecular methods with reduced sensitivity for CNAs.
Interestingly, 17p loss has been previously reported to be prognostic marker for poor survival in other cancers, including brain tumors [14] [15] [16] , bone tumor 17 , periampullary cancer 18 , pancreatic cancer 19 , leukemia 20 , and in CRC 21 evaluated with FISH. These results suggest that 17p loss may be generally useful for predicting patient outcomes. Other large-scale copy number events have been previously identified as prognostic marker for colorectal cancers, e.g. 18q deletion for stages II and III colon cancers 22, 23 , which also lend support to the argument that CNA profiling may be useful for CRC management.
We identified that chromosome arm 17p CNAs occurred consistently in both the discovery and validation cohorts. Minor differences were noted between the two cohorts, as the discovery cohort had chr16p and chr19 amplifications and chr21p deletion while the validation cohort had chr2q amplification and chr14q deletion. These minor differences are likely attributable to the limited cohort size such that not enough samples were available in either cohort for determining the statistical significance of recurrent events presented at lower frequency. It may also reflect the population specific genetics for CRC progression -additional studies will be required to clarify these differences.
We also detected a trend for 17p/TP53 loss as a predictive biomarker for poorer adjuvant chemo-therapy response in Stage III CRC. Although the finding did not achieve statistical significance due to the small cohort size, there are several pieces of additional evidences in the literature for consideration. For example, a recent publication, Oh et al. 24 has found a low-expression of TP53 protein was associated with poor cancer-specific survival in Stage III and high-rick Stage II CRC patients (N=621) who were treated with oxaliplatin-based adjuvant chemotherapy. Additionally, using the TCGA cohort, we found TP53 copy number loss were significantly associated with lower mRNA expression level (P<1e-15, one tailed T-test on Z-normalized mRNA expression levels, see Figure S3 ). All together, these findings suggested that the loss-of-function of TP53 protein, as genetically determined by the focal TP53 gene loss or arm-level chr17p loss, has important prognostic value for late stage CRC patients receiving adjuvant therapies.
To explain the effect of 17p loss, a likely mechanism is increased chromosomal instability, which was observed co-occurring with 17p loss. We analyzed the association between focal and arm-level chromosomal instability and 17p loss and found they were significantly associated with each other. In addition, other studies have shown that 17p loss-of-heterogeneity (LOH) was correlated with CRC's metastatic potential 25 . Similar findings were reported for other cancer types like brain tumor 26 and esophagus cancer 27 . It has been reported that allelic loss of 17p allelic loss was highly correlated with TP53 mutations 28 . All these findings suggest that the loss of 17p is directly related to higher CIN.
There is broad interest in determining which CNAs indicate poor prognosis for individuals with Stage III CRC. We leverage the generally higher resolution of WGS analysis. WGS using a low average sequence coverage is now competitive or at an edge to microarray for both performance and economic reasons. Performance-wise, low-coverage WGS consistently showed high concordance with microarray and high-coverage WGS in our analysis. It As WGS studies become less expensive, we foresee that in the future low-coverage WGS may prove to be replacing clinical microarray testing for cancers 33 , developmental disabilities, congenital anomalies [34] [35] [36] , autism spectrum disorder 37 , and many other genetic diseases 29 . Citing the benefits of WGS, a recent study compared the performance of low-coverage WGS versus microarrays on rare and undiagnosed cases. The conclusion of this study was that robust identification of CNVs was highly feasible with low-coverage WGS 38 .
In another study, low-coverage WGS also found successful application in preimplantation genetic diagnosis of monogenic disease 39 .
METHODS
Discovery cohort ascertainment
The Institutional Review Boards (IRB) from Stanford University and Intermountain
Healthcare approved the study. A total of 134 patients were recruited through the Intermountain Cancer Center (St. George, Utah, USA). Selection criteria involved those diagnosed with Stage III CRC in 2001-2015. We excluded patients who survived less than 90 days after the initial diagnosis and died from non-cancer causes. We collected relevant clinical information from patient medical records, including age of diagnosis, gender, ethnicity, body mass index (BMI), and smoking status (Table 1 and Supplementary Table 1 ).
DNA extraction from clinical samples
We collected matched primary colorectal adenocarcinoma tumor and normal colon tissue samples from each patient (Fig. 1) . All samples were determined to have greater than 60% tumor content in pathology review. We used a two-millimeter punch from a tumor or normal 
Copy number segmentation
For determining which copy number segmentation tool provided accurate results on WGS from FFPE-extracted DNA, we evaluated the copy number callers, CNVkit 41 For each sample, we correlated the WGS-estimated segmental CNRs to the microarray CNRs using 100-kb genome-wide tiles. We computed the Pearson's correlation coefficient (PCC) between the two set of estimates and summarized PCC over all samples by mean and standard deviation. We compared the metric difference between groups using the two-sided T-test. We also conducted a gene-based PCC analysis using the same data.
Next, we evaluated how WGS coverage reduction affects genome segmentation. We applied ~30X high-coverage WGS analysis to eight patients with the identical protocol to lowcoverage WGS. The high-coverage sequence data were down-sampled to low-coverage (~3x) data. We performed genome segmentation using CNVkit on both the high-and low-coverage WGS data. We computed and compared the PCC metrics for high-and low-coverage CNRs based on tumor purity.
WES and targeted sequencing are other common choices for CNA analysis. We also benchmarked low-coverage WGS to high-coverage WES (~300x) in a random subset of 10 patients. We performed genome segmentation using CNVkit on both the high-coverage WES and low-coverage WGS data. We computed and compared the intra-tile deviation metrics of estimated segmental log CNRs based on 100kb genome tiles.
Integrated copy number analysis pipeline
We integrated CNVkit 41 , Gistic2 43 , coxph, survival and glmnet 44, 45 packages of R into our final copy number analysis bioinformatics pipeline (Fig. 1) . We used the data from the genome segments inferred by CNVkit to Gistic2, a cohort CNA caller. We ran Gistic2 with the following arguments: "-refgene hg38.UCSC.add_miR.160920.refgene.mat -maxspace 10000 -ta 0.1 -td 0.1 -qvt 0.25 -broad 1 -brlen 0.7 -twoside 1 -conf 0.99 -genegistic 1 -armpeel 1savegene 1 -res 0.05 -smallmem 1 -js 4". We set the noise cut-off for both deletion and amplification to 0.1. Coupling CNVkit with Gistic2 43 enabled us to identify recurrent arm and focal-level CNAs with statistical significance. We also integrated and ggplot2, survminer, ggpubr, inferCNV R packages 46 for data visualization.
To control for false positives, we identified error-prone CNA regions that demonstrated a high level of CNV background noise using normal DNA samples which had no somatic copy number changes. We ran genome segmentation and CNA calling on all normal DNA samples 10 times and each time with one random normal sample as reference. We compiled all of the CNA calls and identified regions that demonstrated copy number changes in >10% of samples in each run for >5 runs. These changes were likely the result of false copy number calls that were specific to FFPE-extracted DNA, amplification bias or sequencing artifacts.
We filtered out the false positive segments from those noisy regions before conducting the Gistic2 analysis.
Stage III-specific biomarker discovery
We first fitted a multivariate cox model with relevant clinical and demographical covariates to identify any such variables was associated with survival. The full model is as follows: Next, we created binarized CNA variables for each arm-level deletion or amplification (e.g. chr1pdel or chr1pamp for chr1) using the Gistic2 output. The variable is coded one if the CNA amplitude exceeds the noise cut-off, otherwise zero. We fitted a multivariate cox regression model with lasso-regularization to select for candidate CNA biomarkers 47 , including all the 88 arm-level CNA variables, gender, ethnicity, age and treatment.
Finally, we tested the lasso-selected candidate CNA variables' significance by the following multivariate cox regression model: The resulting p-values were adjusted by the Bonferroni correction and significant results were declared with Bonferroni-adjusted P<0.05.
Biomarker validation
CNA biomarkers were validated with an independent cohort of 187 Stage III CRCs from TCGA (Supplementary Table 4 ). We downloaded the overall survival time, survival status, SNP-array based segments, and other clinical data for these patients in the validation co- 
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